Tumour biomarker information was available for 29% (71/241) of patients overall (28%, 44/155 with epithelioid histology; 31%, 27/86 with non-epithelioid histology); in these, the most common biomarker detected (positive expression and/or mutations) was BAP1 (50%, 2/4), followed by PD-L1 (29%, 18/63), VEGF (7%, 1/14), ALK (5%, 2/44) and EGFR (2%, 1/51) (Supplementary Table 1). This evidence concerns the gene EGFR and neoplasm.